Our results warrant further testing of CTLA4 promoter methylation as a predictive biomarker in clinical trials of HNSCC patients treated with anti-PD-1 and/or anti-CTLA-4 immunotherapy. Here, PDCD1 is linked to head and neck squamous cell carcinoma.